Fundraising FoxEvlaBio
4 known investors
Find your way into EvlaBio
Sign up to see every warm intro you have to EvlaBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EvlaBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
Founders & leadership
Investors · 4
AdBio partnerslisted by AdBio partnersParis
How we know: AdBio partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M
How we know: Kurma Partners's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Frequently asked questions
- What does EvlaBio do?
- EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
- Who founded EvlaBio?
- EvlaBio was founded by Robert Kirmeier, Wenzel von der Heydte.
- Who are EvlaBio's investors?
- EvlaBio's investors include AdBio partners, Khanu, Kurma Partners, Boehringer Ingelheim Venture Fund.